Lakeshore Biopharma (LSB) Competitors $2.24 -0.16 (-6.46%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$2.22 -0.03 (-1.34%) As of 02/21/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSB vs. GALT, INZY, ABOS, ENTX, XFOR, CLLS, SCLX, TARA, IGMS, and ALGSShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include Galectin Therapeutics (GALT), Inozyme Pharma (INZY), Acumen Pharmaceuticals (ABOS), Entera Bio (ENTX), X4 Pharmaceuticals (XFOR), Cellectis (CLLS), Scilex (SCLX), Protara Therapeutics (TARA), IGM Biosciences (IGMS), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. Galectin Therapeutics Inozyme Pharma Acumen Pharmaceuticals Entera Bio X4 Pharmaceuticals Cellectis Scilex Protara Therapeutics IGM Biosciences Aligos Therapeutics Galectin Therapeutics (NASDAQ:GALT) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings. Do analysts rate GALT or LSB? Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 638.26%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Galectin Therapeutics is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, GALT or LSB? Galectin Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Is GALT or LSB more profitable? Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% Lakeshore Biopharma N/A N/A N/A Do institutionals & insiders hold more shares of GALT or LSB? 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer GALT or LSB? Galectin Therapeutics received 347 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.11% Underperform Votes24040.89% Lakeshore BiopharmaN/AN/A Which has higher earnings & valuation, GALT or LSB? Galectin Therapeutics has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.73-2.04Lakeshore Biopharma$80.82M0.26-$61.09MN/AN/A Does the media prefer GALT or LSB? In the previous week, Galectin Therapeutics had 2 more articles in the media than Lakeshore Biopharma. MarketBeat recorded 2 mentions for Galectin Therapeutics and 0 mentions for Lakeshore Biopharma. Galectin Therapeutics' average media sentiment score of 0.20 beat Lakeshore Biopharma's score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Galectin Therapeutics Neutral Lakeshore Biopharma Neutral SummaryGalectin Therapeutics beats Lakeshore Biopharma on 8 of the 11 factors compared between the two stocks. Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.29M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.8226.1519.13Price / Sales0.26268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book0.256.717.644.62Net Income-$61.09M$138.55M$3.19B$245.94M7 Day Performance-6.46%-2.63%-2.11%-2.62%1 Month Performance-11.96%-2.33%-0.49%-2.15%1 Year PerformanceN/A-5.33%16.44%12.95% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore BiopharmaN/A$2.25-6.5%N/AN/A$22.29M$80.82M0.00773Gap DownGALTGalectin Therapeutics1.6421 of 5 stars$1.41+8.5%$11.00+680.1%-19.9%$88.49MN/A-1.939INZYInozyme Pharma2.9848 of 5 stars$1.37+1.5%$18.33+1,238.2%-77.7%$88.01MN/A-0.8850News CoverageGap UpABOSAcumen Pharmaceuticals2.4397 of 5 stars$1.45-0.7%$9.33+543.7%-58.4%$87.12MN/A-1.0520ENTXEntera Bio3.0022 of 5 stars$2.43+6.1%$10.00+311.5%+100.0%$86.95M$130,000.00-9.3520Positive NewsXFORX4 Pharmaceuticals4.3718 of 5 stars$0.51+1.2%$3.50+588.3%-46.2%$86.73MN/A-5.6580Gap UpCLLSCellectis2.7423 of 5 stars$1.55+1.3%$7.00+351.6%-46.5%$86.15M$9.19M-1.19290Analyst ForecastGap UpSCLXScilex3.3674 of 5 stars$0.35+1.5%$14.00+3,854.8%-81.4%$86.13M$46.74M-0.4380News CoverageTARAProtara Therapeutics2.0653 of 5 stars$4.16-4.8%$22.67+444.9%-9.7%$85.82MN/A-1.4830IGMSIGM Biosciences4.6088 of 5 stars$1.43+4.4%$5.50+284.6%-89.8%$85.03M$2.13M-0.39190Gap UpALGSAligos Therapeutics4.4988 of 5 stars$23.67+12.7%$75.00+216.9%+11.9%$84.98M$15.53M-1.7890Positive NewsGap Up Related Companies and Tools Related Companies Galectin Therapeutics Competitors Inozyme Pharma Competitors Acumen Pharmaceuticals Competitors Entera Bio Competitors X4 Pharmaceuticals Competitors Cellectis Competitors Scilex Competitors Protara Therapeutics Competitors IGM Biosciences Competitors Aligos Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
